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1. Introduction 
Cardiovascular diseases have similar pathophysiologic mechanisms which lead patient from 
risk factors, such as dyslipidemia, smoking, high blood pressure etc. to congestive heart 
failure and finally – to death (Fig. 1.). This global approach to the natural history of cardiac 
pathology has been proposed at the end of the twentieth century and remains current till 
now (Cheung, 2006). Thyroid dysfunction is a common clinical problem which plays a key 
role in the regulation of the cardiovascular system and can contribute to the clinical course 
of coronary artery disease (CAD). As it was shown on Fig.1 thyroid dysfunction can affect 
almost all chains of this continuum and its influence should be taken into account when 
treating patients with CAD. 
In several studies the presence of predominantly adverse cardiac effects of thyroid 
dysfunction on the natural history of CAD has been shown (Iervasi et al., 2007). Thyroid 
diseases are associated with systolic and diastolic cardiac dysfunction, hypertension, heart 
rhythm disorders etc. Overt hypo- as well as hyperthyroidism affect outcomes in patients 
with CAD. As it has been recently shown in numerous studies, even subclinical 
hyperthyroidism can be an independent risk factor for all-cause and cardiovascular 
mortality (Sgarbi et al., 2010). Previously subclinical hypothyroidism was recognized as an 
independent risk factor for atherosclerosis and myocardial infarction in elderly women (Hak 
et al., 2000). But results of these studies are sometimes controversial (Biondi, 2010; Cappola 
et al., 2006; Iervasi et al., 2007; Ittermann et al., 2010)  
Thyroid hormone excess causes a lot of cardiovascular changes due to both direct and 
indirect effects on the cardiovascular system (Table 1), and results in neurohormonal 
activation, including sympathetic nervous system activation. The latter determines 
increased heart rate and appearance of arrhythmia, especially atrial fibrillation. 
Hyperthyroidism is also associated with hypertension and CAD clinical manifestation.  
With aging, physiological changes in thyroid homeostasis interact with different 
cardiovascular risk factors (Mariotti, 2008). Hypothyroidism is frequently found in the 
elderly, may cause several functional cardiovascular abnormalities and increases the risk of 
atherosclerosis and CAD manifestation (Mariotti & Cambuli, 2007). Hypothyroidism alters 
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lipid metabolism, which contributes to the natural course of CAD. Hypertension can be also 
a clinical sign of thyroid hypofunction. Hypothyroidism may result in diastolic and systolic 
cardiac dysfunction, i.e. heart failure. Other its potential cardiovascular risk factors are 
increased circulating C-reactive protein and homocysteine levels, increased arterial stiffness, 
endothelial dysfunction, and altered coagulation parameters (Mariotti & Cambuli, 2007). On 
the contrary, some investigators had found that hypothyroidism is not associated with an 
increased risk of carotid atherosclerosis (Chiche et al., 2009). On the other hand, Mazzeffi et 
al. (2010) confirmed the association between hypothyroidism and lower extremity arterial 
disease as an atherosclerosis display. So, after years of research there are still unexplored 
facts waiting to be resolved. 
 
Fig. 1. Cardiovascular continuum and thyroid dysfunction (modified from Dzau & 
Braunwald, 1991). 
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- Impact of thyroid dysfunction has been established 
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Pathways Clinical manifestations 
Effects predominantly on cardiomyocytes: 
1. On the genome level (prolonged effects): in the nucleus triiodthyronine interacts with specific 
transcriptional activators or repressors and alters the transcription modality of specific target 
genes (Brent, 1994). Triiodthyronine contributes to: 
-protein synthesis and thus transcriptional activation of ǂ-isoform of myosin heavy chain, 
sarcoplasmic reticulum calcium-activated adenosine triphosphatase, ǃ1-adrenergic receptors, 
guanine-nucleotide-regulatory proteins, Na+/K+-adenosine triphosphatase, some of voltage-
gated K+ channels (Fazio et al, 2004; Kahaly & Dillmann, 2005) 
-transcriptional repression of ǃ-isoform of myosin heavy chain, phospholamban, nuclear receptor ǂ1, 
adenylyl-cyclase types V & VI, Na+/Ca2+ exchanger (Fazio et al., 2004; Kahaly & Dillmann, 2005) 
2. Extranuclear cellular mechanisms (short-term effects): 
Effects on membrane 
Augmented activity of the sinoatrial node (Sun et 
al., 2001) through increasing the conductance 
density of I(f)-channels (Renaudon et al., 2000) 
Increased heart rate and myocardial oxygen 
demand 
Activation of transmembrane transfer of sodium 
and potassium (Kahaly & Dillmann, 2005), calcium 
(Kiss et al, 1994) and glucose (Chidakel et al., 2005) 
Activation of cardiomyocytes’ metabolism  
Effects on sarcoplasmic reticulum 
Activation of calcium reuptake during diastole,  
up-regulation of calcium-activated adenosine 
triphosphatase, down-regulation of phospholamban 
expression (Fazio et al., 2004; Kiss et al., 1994; Ojamaa 
et al., 2002)   
Augmented contraction of cardiomyocytes, 
enhancing myocardial relaxation  
Effects on mitochondria 
Activation of oxidative phosphorylation 
(Verhoeven et al., 1985) 
Activation of cardiomyocytes’ metabolism 
Activation of adenine nucleotide translocase 
(Sterling, 1986) 
Activation of cardiomyocytes’ metabolism 
Effects on heart: 
Increased density of cardiac ǃ1-adrenoreceptors 
(Kahaly & Dillmann, 2005) and, thus, response to 
catecholamines  
Elevation of cardiac output 
Effects on vascular wall: 
Relaxation effect on vascular smooth-muscle cells 
(Ojamaa et al., 1996) 
Vasodilatation, decreased preload as well as 
afterload on the heart, decreased peripheral 
vascular resistance  
Other effects of thyroid hormone, which have influence on the natural course of 
cardiovascular diseases: 
Activation of metabolism Increased myocardial oxygen demand 
Effects on lipid profile (Rizos et al., 2011) Maintaining serum very low-, low- and high-
density lipoprotein cholesterol, triglyceride and 
apo-B 100 levels within normal range  
Modulation of glucose production and glycogen 
storage in the liver and heart (Boelen, 2009; 
Forhead et al., 2009; Klieverik et al., 2009) 
Activation of cardiomyocytes’ metabolism  
Increase sodium reabsorbtion in the kidney 
(Capasso et al., 1999) 
Increase circulation blood volume 
Table 1. The most important effects of thyroid hormone on the cardiovascular system. 
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There are also several challenges of CAD treatment in patients with coexisting thyroid 
dysfunction. Usage (especially long-term, with high doses) of amiodarone per se can result in 
amiodarone-induced thyroiditis and thyroid dysfunction (Iervasi et al., 1997; Martino et al. 
2001). Different ǃ-blockers show dissimilar effects on thyroid hormone levels, and these 
responses should be taken into account when treating patients with CAD and coexisisting 
thyroid dysfunction. There is a wide discussion about safety of levothyroxine replacement 
treatment in patients with CAD. It is known that this therapy can improve results of cardiac 
function measurements in subjects with hypothyroidism, however in the presence of CAD 
levothyroxine replacement treatment may result in manifestation or worsening of the CAD 
symptoms (Mariotti & Cambuli, 2007).  
New data emerged about association between thyroid dysfunction and CAD natural 
history, which will be discussed hereafter. During the last decades interest to the influence 
of subclinical thyroid dysfunction on CAD progression rises significantly, but findings are 
still too controversial to make definitive decision. By now even definition for normal serum 
thyroid hormone and thyrotropin range is still not completely established. This chapter will 
be dedicated to the main problems of coexisting CAD and overt thyroid dysfunction. 
Influence of subclinical thyroid dysfunction on CAD will not be discussed in this chapter 
because of the immensity and complexity of the issue. 
2. Impact of hypothyroidism on the natural history of CAD 
Hypothyroidism can influence the natural course of CAD in different ways. In patients with 
overt hypothyroidism hyperlipidemia, coagulation abnormalities, endothelial dysfunction, 
hypertension, hypertrophy and diastolic dysfunction of heart ventricles, and abnormalities 
of insulin resistance had been found. Most of these factors can alter atherosclerotic process 
and modify morbidity and mortality rates for CAD. But after decades of research 
implication of thyroid hypofunction in CAD progression is still unclear and needs to be 
reassessed. 
2.1 Effects of overt hypothyroidism on the most important cardiovascular risk factors: 
hyperlipidemia and hypertension 
2.1.1 Hypothyroidism and hyperlipidemia 
The role of lipid metabolism disorders in pathophysiologic mechanisms of atherosclerosis, 
following CAD and its complications is well established. Hyperlipidemia is a first step of the 
cardiovascular continuum; it is widely known as an independent cardiovascular risk factor. 
Clear and exact recommendations addressed to the lipid levels control, especially in patients 
with CAD and those at high cardiovascular risk were developed. It is also generally 
accepted that hypothyroidism accelerates development of CAD by its impairment action on 
lipid metabolism (Jung et al., 2003; Rizos et al., 2011). Hyperlipidemia is more often 
observed in patients with serum concentration of thyrotropin more than 10 mIU/L (Biondi 
& Klein, 2004).  
The most important mechanisms of thyroid hormone action on lipid metabolism are shown 
in Table 2. 
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Mechanism Result Impact on the course of CAD in 
case of hypothyroidism 
Inducing the HMG-CoA reductase Cholesterol 
biosynthesis 
Theoretically depressed cholesterol 
production, but in practice 
increased total cholesterol and LDL 
cholesterol levels due to decreased 
catabolism of LDL and IDL 
cholesterol  
Controlling the LDL receptor gene 
activation (for T3) by: 
-the direct binding to specific 
thyroid hormone responsive 
elements (Rizos et al., 2011) 
-controlling the sterol regulatory 
element-binding protein-2 (Shin & 
Osborne, 2003) 
Up-regulation of LDL 
receptors  
Decreased catabolism of LDL and 
IDL cholesterol, increased total 
cholesterol and LDL cholesterol, 
acceleration of atherosclerosis and 
CAD  
Controlling the TG levels by 
hypotriglyceridemic gene APOA5 
regulation (Prieur et al., 2005) 
Inhibition of TGs 
production 
Increased TG levels, acceleration of 
atherosclerosis and CAD  
T3 and its acetic derivative protect 
LDL from oxidation (Faureet al., 
2004) 
Protection from 
oxidation of LDL  
Burden of oxidative stress, 
acceleration of atherosclerosis and 
CAD  
Increased cholesteryl ester transfer 
protein activity 
Increased exchange of 
cholesteryl esters from 
HDL2 to VLDL and 
TGs to the opposite 
direction (Rizos et al., 
2011) 
Not definitely established, due to 
this mechanism plasma HDL levels 
may be elevated 
Stimulation of lipoprotein lipase Activation of TG-rich 
lipoproteins catabolism 
(Rizos et al., 2011) 
Decreased clearance of TG-rich 
lipoproteins, hypertriglyceridemia, 
acceleration of atherosclerosis and 
CAD  
Stimulation of hepatic lipase Activation of 
hydrolyzation HDL2 to 
HDL3, conversion of 
IDL to LDL and in turn 
LDL to small dense 
LDL (Rizos et al., 2011) 
Increased levels of HDL2, IDL and 
LDL. Impact on the natural history 
of CAD is controversial 
Up-regulation of apoAV Decreased hepatic TGs, 
VLDL production, 
increased both plasma 
lipoprotein lipase levels 
and activity, enhanced 
affinity for the LDL 
receptor, greater 
clearance of lipoprotein 
core remnants (Rensen 
et al., 2005)  
Increased plasma TG and VLDL 
levels; acceleration of 
atherosclerosis and CAD  
Table 2. The most important mechanisms of thyroid hormone action on lipid metabolism 
and their impact on the course of CAD in case of hypothyroidism. HMG-CoA = 3-hydroxy-
3-methylglutaryl-coenzyme A; LDL = low-density lipoprotein; IDL = intermediate-density 
lipoprotein; T3 = triiodthyronine; TG = triglyceride; HDL = high-density lipoprotein;  
VLDL = very low-density lipoprotein 
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Therefore overt thyroid hypofunction primarily leads to elevated plasma total cholesterol 
and low-density lipoprotein cholesterol levels. Elevation of triglyceride levels is also 
possible as well as increased concentration of high-density lipoprotein cholesterol (mainly 
because of increased concentration of high-density lipoprotein–2 particles). So, lipid profile 
in patients with hypothyroidism has atherogenic properties, and may be characterized by 
unusual condition with simultaneously elevated triglycerides and high-density lipoprotein 
cholesterol levels despite it is widely accepted that hypothyroidism is associated with 
decreased high-density lipoprotein cholesterol levels (Cappola & Ladenson, 2003) and that 
there is an inverse relation between these two measures. Thus, atherogenic lipid profile in 
patients with overt hypothyroidism may be partly diminished by this elevated plasma 
concentration of high-density lipoprotein cholesterol. It was also shown that patients with 
hypothyroidism have increased concentration of lipoprotein (a) – known by its atherogenic 
facilities and associated with atherosclerotic artery lesion, particularly CAD (Rizos et al., 
2011; Tzotzas et al., 2000).  
2.1.2 Hypothyroidism and hypertension 
Hypertension is another strong cardiovascular risk factor and the starting point of the 
cardiovascular continuum. Hypertension has a great influence on the natural course of CAD 
resulting in an increase in cardiac afterload, ventricular hypertrophy, impairment of diastolic 
function of ventricles as well as endothelial dysfunction and neurohormonal activation (Dzau 
& Braunvald, 1991). Hypothyroidism prevalence among general population of patients with 
hypertension reaches 3-4%, and it was established that patients with hypothyroidism and 
hypertension represent higher blood pressure levels compared with those without thyroid 
dysfunction (Fommei & Iervasi, 2002; Saito, 1983). At the same time hypertension is more 
common in hypothyroid population – its prevalence reaches 20-40% (Klein & Ojamaa, 1995; 
Streeten et al., 1988). So, hypertension is a frequent symptom of hypothyroidism and 
independent risk factor for cardiovascular events, morbidity and mortality, particularly CAD-
associated. As it was shown in several studies, thyroid hypofunction is associated with 
predominantly diastolic hypertension as a result of increased systemic vascular resistance, 
increased arterial stiffness and impaired endothelial function (Biondy & Klein, 2004; Dernellis 
& Panaretou, 2002; Kanbay et al., 2007; Obuobie et al., 2002).  
Hypothyroid patients have significantly higher diastolic blood pressure levels in the fifth 
and sixth decades of life (time of CAD manifestation in most cases) compared with measures 
in euthyroid controls (Aronow et al., 2011). Iqbal et al. (2006) have shown in their study of 
5,872 subjects (2,623 male subjects) without antihypertensive or replacement levothyroxine 
treatment, that even within the normal serum thyrotropin range (0.20–4.00 mIU/L) there was a 
modest, but significant and positive association between serum thyrotropin and both systolic 
and diastolic blood pressure levels. Serum thyrotropin levels were higher in the hypertensive 
subjects, but differences were significant only for diastolic hypertension. The same trend was 
found by group of Norwegian scientists (Åsvold et al., 2007a).  
2.2 Hypothyroidism, atherosclerosis and CAD 
In one of the recent reviews addressed to the problem of the association between CAD and 
hypothyroidism Cappola & Ladenson (2003) mentioned: “…today’s clinicians managing 
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patients with hypothyroidism and atherosclerosis are still guided more by medical folklore 
than evidence-based medicine”. It is widely accepted that hypothyroidism adverse 
contributes to the natural course of CAD (Miller & Gambert, 2008), but most of the studies, 
aimed to proof this postulate, are outdated, not large enough and have serious limitations. 
Most of them have been conducted in patients with subclinical hypothyroidism and/or 
predominantly in women. For example, findings of Vanhaelst et al. (1967) have been based 
on autopsy data of 25 patients with myxoedema and suggest that intensity of atherosclerotic 
disease was significantly higher in hypothyroid compared with euthyroid patients. But 
results of the Cardiovascular Health Study of 3,678 men and women didn’t establish any 
prepotency of angina, myocardial infarction, transient ischemic attack, stroke and peripheral 
arterial disease in patients with subclinical hypothyroidism compared with such prevalence 
in euthyroid people (Ladenson et al, 1994). In the frequently cited study, performed by Perk 
& O`Neill and published in 1997, the authors found angiographic CAD progression 
differences for only 10 participants with hypothyroidism compared with those on adequate 
replacement therapy.  
Interestingly, the evidence body of the association between overt hypothyroidism and CAD 
was proposed mostly by studies of not overt, but subclinical hypothyroidism, possibly 
because of its wider prevalence. The Wickham Survey, first large-scale examination of the 
relationship between thyroid function and cardiovascular outcomes, enrolled 2,779 men and 
women. Overt hypothyroidism was an exclusion criteria, 132 persons have subclinical 
thyroid hypofunction (Vanderpump et al., 1996). In a 20-yr follow-up of this population-
based cohort study any relationship between incident CAD or mortality and composite 
variable of hypothyroidism on replacement therapy, presence of circulating antithyroid 
antibodies, and/or thyrotropin level more than 6 mIU/L was not established in both men 
and women. But replacement treatment was the most important limitation, which could cause 
shift in indexed results (Cappola & Ladenson, 2003). The Rotterdam Study of 1,149 women 
(age 55 years or older) was another study of subclinical hypothyroidism which proves the 
possibility of hypothyroidism to affect the natural course of atherosclerosis and to increase 
CAD-morbidity (Hak et al., 2000). It was shown after adjustment for age, smoking status, body 
weight index, blood pressure, and high-density lipoprotein cholesterol levels, that women 
with subclinical hypothyroidism had higher prevalence of aortic atherosclerosis on chest 
radiograms (odds ratio [OR] 1.9; 95% confidence interval [CI] 1.2-3.1) and higher prevalence of 
myocardial infarction (OR 2.3; 95% CI 1.3-4.2) compared with euthyroid ones.  
Prevalence of obstructive CAD in patients with diabetes mellitus depending on the presence 
of hypothyroidism was shown in the study, conducted by Pierre-Louis et al. (2008). In this 
study totally 352 patients with diabetes mellitus underwent coronary angiography because 
of recent myocardial infarction or unstable angina or chest pain with a positive stress test. 
More than 50% narrowing of 1 or more major coronary arteries was present in 145 of 173 
patients (84%) with diabetes mellitus and hypothyroidism and in 132 of 179 patients (74%) 
with diabetes mellitus without hypothyroidism (p<0.025). More than 50% narrowing of 3 
major coronary arteries was present in 69 of 173 patients (40%) with diabetes mellitus and 
hypothyroidism and in 39 of 179 patients (22%) with diabetes mellitus without 
hypothyroidism (p<0.001). So, these findings represent evidence that patients with diabetes 
mellitus and hypothyroidism have higher prevalence and intensity of CAD compared with 
patients with diabetes mellitus without hypothyroidism.  
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One recent study provides some kind of confirmation of the association between 
hypothyroidism and lower extremity arterial disease as an atherosclerosis display (Mazzeffi 
et al., 2010). Six hundred fourteen patients and 529 control cases were enrolled, and gender 
was found to be a significant confounder. In men there was a positive independent 
association between hypothyroidism and lower extremity arterial disease (adjusted OR 2.65; 
95% CI 1.19-5.89), whereas in women there was a negative independent association 
(adjusted OR 0.22; 95% CI 0.11-0.46).  
Thus, despite of widely accepted opinion about ability of hypothyroidism to accelerate the 
natural course of CAD, carefully designed large controlled studies are still needed to prove 
this point of view conclusively.  
3. Impact of hyperthyroidism on the natural history of CAD  
Hyperthyroidism can alter the natural course of CAD in several ways. First of all it increases 
myocardial oxygen demand together with sinus and/or supraventricular tachycardia (as well 
as atrial fibrillation) – these factors can contribute to decompensation of underlying CAD and 
lead to manifestation of angina pectoris and heart failure (mostly with high cardiac output). 
Furthermore, systolic blood pressure is usually increased, while diastolic blood pressure – 
decreased in patients with hyperthyroidism. Due to this pulse pressure becomes wider and 
mean blood pressure – moderately decreased. These changes are associated with an increase in 
cardiac output and reduction in peripheral vascular resistance, resulting in the classic 
hyperdynamic cardiovascular status (Fazio, et al., 2004). Cardiac preload is increased and 
blood volume is enlarged in patients with hyperthyroidism, there are also conditions for 
diastolic dysfunction of heart ventricles due to above-listed factors and tachycardia. 
Hyperthyroidism affects one more chain of the cardiovascular continuum: renin-angiotensin-
aldosterone system is activated in patients with thyroid hyperfunction (Resnick & Laragh, 
1982). It was also shown that hyperthyroidism is associated with elevation of von Willebrand 
factor levels as well as enhanced platelet function and therefore shortened collagen-
epinephrine-induced closure time (platelet plug formation measure) (Homoncik et al., 2007). 
The presence of CAD may compromise the ability of myocardium to respond to the metabolic 
demands of hyperthyroidism (Kahaly & Dillman, 2005). Hyperthyroidism may cause 
myocardial infarction even in subjects without coronary stenosis (Cowda et al., 2003; Jaber et 
al., 2010; Moliterno et al., 1992). There were also described such changes which can influence 
the natural course of CAD as necrosis of myocytes, small areas of fibrosis or round-cell 
infiltration in the hearts of patients with hyperthyroidism (Kahaly & Dillman, 2005).  
The prevalence of cardiac decompensation in hyperthyroid patients with advancing age was 
established (Davis & Devis, 1975; Kahaly & Dillman, 2005; Trivalle et al., 1996). In patients 
over 50 years of age cardiovascular complications are the leading cause of death after 
treatment of hyperthyroidism (Franklyn et al., 1998). Supraventricular arrhythmias in older 
patients may contribute to some of the excess cardiovascular mortality as it was shown in 
several long-term follow-up studies (Franklyn et al., 1998; Parle et al., 2001; Osman et al., 
2002). In one population-based study (Franklyn et al., 1998) of mortality with standardized 
mortality ratio (SMR) as a measure of relative risk in a cohort of 7,209 patients with 
hyperthyroidism treated with radioiodine it was shown, that during 105,028 person-years of 
follow-up, 3,611 subjects died; the expected number of deaths was 3,186 (SMR 1.1; 95% CI 
1.1-1.2; p<0.001). The risk was increased for deaths due to cardiovascular disease (240 excess 
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deaths; SMR 1.2; 95% CI 1.2-1.3; p<0.001), and cerebrovascular disease (159 excess deaths; 
SMR 1.4; 95% CI 1.2-1.5; p<0.001). Rheumatic disease (46 excess deaths, SMR 3.2; 95% CI 2.5-
4.2; p<0.001) and hypertensive heart disease (31 excess deaths, SMR 2.1; 95% CI 1.6-2.7; 
p<0.001) had the highest SMRs. On the other hand, SMR for ischemic heart disease was 
modest (SMR 1.1; 95% CI 1.0-1.1; p=0.03) with 55 excess deaths. Intriguingly, in this study 
after separate analyses for men and women the excess deaths due to the cardiovascular 
disease was established for women but not for men (women: SMR 1.3; 95% CI 1.2-1.4; men: 
SMR 1.0; 95% CI 0.9-1.2; p<0.001 for the comparison between men and women).  
So, the most important confounders for cardiovascular morbidity and mortality of 
hyperthyroid patients are dysrhythmias (especially atrial fibrillation) with tromboembolic 
complications, and hypertension. Gender of the patient may also have some influence on the 
clinical course of cardiovascular diseases in patients with hyperthyroidism. 
4. Cardiovascular risk factors in patients with different thyroid status:  
Our findings 
Recently we conducted a retrospective study, which took place in two medical centres in Kiev 
(Ukraine), aimed to establish prevalence of the main cardiovascular risk factors in 464 
consecutive patients with CAD depending on their thyroid status, stratified into 3 groups: 
euthyroid (n=115, mean age 57.4±0.8 years, 76.5% female, mean thyrotropin level 1.6±0.12 
mIU/L), hypothyroid (n=108, mean age 56.8±1.1 years, 76% female, mean thyrotropin level 
12±1.7 mIU/L), and hyperthyroid (n=241, mean age 55.4±0.6 years, 86.7% female, mean 
thyrotropin level 0.16±0.03 mIU/L). Medical records were estimated and all patients, who met 
inclusion criteria (registered CAD and/or prescribed antiischemic therapy together with 
defined thyroid status), were included in our study. During statistical analysis continuous 
variables were expressed as mean±error of mean, categorical variables were expressed as 
frequency and percentage. Comparison between variables was performed using analysis of 
variance and the Student t test. A p value less than 0.05 was considered statistically significant. 
The prevalence of hypertension was high in all groups with the highest rate for hypothyroid 
group (Fig.2). For hyperthyroid patients there was a trend for the increased prevalence of 
grade 1-2 hypertension, and less prevalent (approximately 2.1 times) grade 3 hypertension 
compared with rates in the euthyroid group. There was also significantly increased rate of 
grade 1-2 hypertension in hypothyroid patients compared with rate in the euthyroid group 
(see Fig.2). 
We didn’t find any significant differences in lipid profile among these 3 groups: total 
cholesterol, low-density lipoprotein and triglyceride levels were somewhat elevated in all 
groups, the only difference was obtained for high-density lipoprotein level, which was 
26.6% lower in hypothyroid compared with euthyroid group of patients (Fig.3), but still 
within the normal range. These findings are consistent to the results of several studies 
(Cappola & Ladenson, 2003), but disagree with statement of Rizos et al. (2011) about 
possibility of high-density lipoprotein levels increasing in hypothyroid patients, likely due 
to mild-to-moderate hypothyroidism in our study (mean thyrotropin level 12±1.7 mIU/L). 
On the other hand, our results didn’t show any significant differences in lipid profile 
between patients with CAD depending on thyroid status. This finding suggests that these 
changes were determined by alternative mechanisms, and their consequences are almost 
irrespective of thyroid status when it comes to moderate but overt thyroid dysfunction.  
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Fig. 2. Prevalence of hypertension in patients with CAD depending on thyroid status. p 
indicates statistical significance for comparison with euthyroid group. 
 
 
Fig. 3. Lipid profile in patients with CAD depending on thyroid status. p indicates statistical 
significance for comparison with euthyroid group. TC = total cholesterol, LDL = low-density 
lipoprotein, HDL = high-density lipoprotein, TGs = triglycerides. 
p<0.05
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Fig. 4. Proportion of patients with body weight index more than 25.5 m/kg among those 
with CAD depending on thyroid status. p indicates statistical significance for comparison 
with euthyroid group, p1 – statistical significance for comparison with hypothyroid group. 
BWI = body weight index.  
In the course of body weight index estimation we had obtained expected results: patients 
with hyperthyroidism had better measures compared with other groups. Less than ¼ 
subjects of the hyperthyroid group had body weight index > 25.5 m/kg (Fig.4). In our study 
proportion of overweight patients in the hypothyroid group was more than ⅓ and in the 
euthyroid group – a little less than ½. We couldn’t estimate waist circumference and waist-
to-hip ratio, both the definite cardiovascular risk factors, because of the retrospective design 
of the study and lack of these data in medical records. 
Our results regarding glycaemic status of the patients with CAD and thyroid dysfunction 
were surprising enough (Fig.5 & 6). Despite of being within normal limits, mean fasting 
plasma glucose level for patients in hyperthyroid group was significantly lower compared 
with such in euthyroid group (see Fig.5). This result was consistent to another one: in our 
study proportion of patients with fasting plasma glucose level > 102 mg/dL (5.6 mmol/L) 
was the smallest for hyperthyroid population (16.2%) compared with euthyroid (33%, 
p<0.001) and hypothyroid (25.9%, p>0.05) groups (see Fig.6). Fasting plasma glucose level 
>102 mg/dL is known cardiovascular risk factor influencing prognosis of the patients with 
hypertension (Mancia et al., 2007), and is important for patients with hyperthyroidism and 
CAD associated with increased prevalence of hypertension. This relatively lower level of 
fasting plasma glucose is probably linked to both activation of metabolism (particularly 
carbohydrate metabolism) and sensitivity to insulin, and reflects more intense glucose 
uptake by cells. There weren’t any significant differences in diabetes prevalence between 
study groups (all p>0.05).  
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Fig. 5. Fasting plasma glucose levels in patients with CAD depending on thyroid status. p 
indicates statistical significance for comparison with euthyroid group. 
 
Fig. 6. Glycaemic status and prevalence of cardiovascular risk factors in patients with CAD 
depending on thyroid status. p indicates statistical significance for comparison with 
euthyroid group. 
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We also investigated the prevalence of  previous main cardiovascular events: myocardial 
infarction and stroke in patients with CAD and different thyroid status (Fig.7). According to 
our data, in the euthyroid group prevalence of previous myocardial infarction was more 
than 2 times higher compared with such in hyperthyroid group (13.9% vs. 5%, respectively, 
p<0.01). In our study there weren’t any statistically significant differences in the rates of 
stroke between study groups, which was really unexpected because of general opinion, that 
hyperthyroidism is strongly associated with stroke as a thromboembolic complication of 
atrial fibrillation (Franklyn et al., 1998). The lowest rate of previous myocardial infarction in 
this hyperthyroid group partly denies assumption that mild but not subclinical thyroid 
hyperfunction can definitely cause serious worsening of the natural course of CAD, and this 
hypothesis still needs careful and well designed investigation. 
 
Fig. 7. Prevalence of previous cardiovascular events in patients with CAD depending on 
thyroid status. p indicates statistical significance for comparison with euthyroid group. 
5. Conclusion 
Despite numerous studies dedicated to the interaction between cardiovascular system and 
thyroid, a lot of issues are still unclarified. The results of different authors are often 
controversial first of all because of extreme difficulties in designing of such studies. The 
most problem of thyroid status identification and evaluation is its instability within the 
natural course of thyroid diseases. During years of illness thyroid function can be changed 
from activated to moderate activated, “normal” by results of several screening tests, and 
then - decreased. But if thyroid tissue is relatively preserved, it’s absolutely possible, that 
thyroid function at times may become increased or “normal” again necessary amount of 
thyroid cells are available. This instability may cause selection bias during studies.  
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There is also a wide discussion about normal range of main markers of thyroid dysfunction: 
serum thyrotropin, triiodthyronine, thyroxine levels (Surks et al., 2004). Taking into 
consideration current complex classification of thyroid disorders, which is based on these 
marker levels,  a new question arises: do we use the proper criteria for definition of thyroid 
dysfunction and dysfunction of different organs due to thyroid hormone changes, 
particularly cardiovascular system? What about tissue sensibility to thyroid hormone in 
patients with CAD? It is still unclear, how works thyroid hormone in people with 
cardiovascular diseases: atherosclerosis and CAD? Is this mechanism similar or not to such 
in healthy subjects? What are the differences? Can genetic features of the patients with 
cardiovascular disease, which predispose a person to atherosclerosis and CAD, influence 
normal or pathological thyroid?  
Recently emerging evidence indicates that 45–65% of the inter-individual variation in serum 
thyroid hormone levels is due to genetic factors (Medici et al., 2011). In one study 68 genes 
(1512 polymorphisms) were studied in relation to serum thyrotropin and thyroxine levels in 
1,121 Caucasian subjects. It was shown that for thyrotropin 8 PDE8B polymorphisms 
(p=4×10−17) and for thyroxine 2 DIO1 (p=8×10−12) and 1 FOXE1 (p=0.0003) polymorphisms 
remained significant in the meta-analysis (Medici at al., 2011). In the meta-analysis of 2,557 
patients Taylor et al. (2011) have clarified associations between the rs4704397 single 
nucleotide polymorphism in PDE8B and thyrotropin, triiodothyronine and thyroxine levels. 
This meta-analysis confirmed presence of genetic variation in PDE8B associated with 
thyrotropin (p=1.64×10−10) and identified a possible new association with free thyroxine 
(p=0.023). Taylor et al. (2011) suggest that common genetic variation in PDE8B is associated 
with reciprocal changes in thyrotropin and free thyroxine levels that are consistent over time 
and lost in individuals on levothyroxine therapy. These both results are intriguing because 
they display possible genetic markers of variation in serum thyroid hormone levels that will 
be helpful in designing and carrying out epidemiological studies.  
Treatment of both thyroid and cardiovascular diseases can contribute to pathways and 
outcomes, but till now we know little about this. Some studies were dedicated to the 
evaluation of influence of hyperthyroidism treatment strategies on cardiovascular outcomes 
(Hall et al., 1993; Franklyn et al, 1998), but precise mechanisms of their action are still 
unclear. One of the recent treatment approaches for hyperthyroidism is so called “suppress 
and replace” management with complete suppression of thyroid function (marker – 
thyrotropin levels) and simultaneously replacement therapy with thyroid hormone (Kahaly 
& Dillmann, 2005). This condition and its possibility to influence the cardiovascular system 
should be carefully established. In some cases of treatment with levothyroxine it is possible 
even in previously hypothyroid patients appearance of “tissue hyperthyroidism” on cardiac 
level (normal thyroxine and triiodthyronine and suppressed thyrotropin) (Banovac et al., 
1989). The fact that euthyroid due to the replacement therapy hearts are not similar to those 
euthyroid without such therapy were discussed elsewhere (Bengel et al., 2000; Biondi et al., 
1996), but we need more evidence. 
It is also widely known that cardiovascular diseases may contribute to the thyroid function 
predominantly causing its down-regulation. In one study it was shown, that patients with 
CAD during acute phase of myocardial infarction demonstrated a rapid and sustained fall 
in serum total triiodothyronine concentration, a rise in reverse triiodothyronine 
concentration, and a transient fall in total thyroxine concentration. This observed fall in 
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triiodothyronine concentration wasn’t accompanied by significant changes in basal 
thyrotropin concentrations (Franklyn et al., 1984). In another study of 47 consecutive 
euthyroid patients with acute myocardial infarction thyroid status also was evaluated 
(Friberg et al., 2002) with mostly similar results. The study had demonstrated that thyroid 
hormone was rapidly down-regulated with maximal development by 24-36 hours after 
onset of symptoms. The mean of serum total triiodothyronine concentration decreased by 
19% (p=0.02), the mean of serum reverse triiodothyronine concentration increased by 22% 
(p=0.01), while serum thyrotropin concentration decreased by 51% (p<0.001) between the 
first 6-hour of myocardial infarction and 24-36-hour time interval. Notably, patients with 
severe heart dysfunction or more intense inflammatory reaction showed more pronounced 
down-regulation of the thyroid function. Interestingly, serum free thyroxine levels was 
predominantly unchanged in both studies (Franklyn et al., 1984; Frieberg et al., 2002). This 
adaptive reaction provides reduction of myocardial oxygen demand and relieves emerged 
mismatch between myocardial oxygen demand and oxygen delivery in patients with CAD. 
On the other hand, in several studies association between thyrotropin levels (even within 
reference range) and body weight index, the occurrence of obesity (Knudsen et al., 2005), 
and serum lipid concentrations (Åsvold et al., 2007b) was found. In 2008 Åsvold et al. had 
published their new results from the Nord-Trøndelag Health study (the HUNT study) about 
association between CAD mortality and relatively low thyroid function within the clinical 
reference range. Total 25,313 patients without history of thyroid disease, angina, myocardial 
infarction, stroke or diabetes mellitus at baseline were enrolled. At the end of follow-up 
(median 8.3 years) 228 women (1.3%) and 182 men (2.3%) died of CAD (192 women and 164 
men of them had thyrotropin levels within the reference range). The presence of positive 
association of thyrotropin level within the reference range with risk of fatal CAD was shown 
(p for trend=0.01 in the total population and p for trend=0.007 in non-smokers), especially in 
women (p for trend=0.005). Compared with women in the lower part of reference range 
(thyrotropin level 0.5-1.4 mIU/L) hazard ratios were 1.41 (95% CI 1.02-1.96) and 1.69 (95% 
CI 1.14-2.52) for women in the intermediate (thyrotropin level 1.5-2.4 mIU/L) and higher 
(thyrotropin level 2.5-3.5 mIU/L) parts of the reference range, respectively (Åsvold et al., 
2008). These results suggest that relatively low but clinically normal thyroid function may 
increase the risk of fatal CAD, especially in non-smoking women. 
In Czech Republic Mayer et al. (2006) conducted a study aimed to ascertain the prevalence 
of hypothyroidism in 410 patients (303 men and 107 women) with manifest CAD and to 
establish its association with cardiovascular risk factors. The prevalence of hypothyroidism 
(overt & subclinical) in the total sample and among male and female patients was 11.2, 6.9 
and 23.4%, respectively. Overt hyperthyroidism (thyrotropin level> 3.65 mIU/L and free 
thyroxine <9 pmol/L and/or levothyroxine substitution) in this study was detected in 4.1% 
of total sample, 2.6% male and 8.4% female patients. Interestingly, there weren’t any 
differences in hyperthyroidism prevalence: for total sample and separately male and female 
patients it was 5.6%. On the other hand, in this study the high prevalence of diabetes type 2 
was found for the total sample (was not shown) with mean of fasting plasma glucose levels 
ranged from 6.7 to 7.6 mmol/L in euthyroid and hypothyroid groups without statistical 
difference. This finding is somewhat controversial to our results, but it can be explained by 
differences in the study samples: Mayer et al. (2006) enrolled only those who had survived 
after acute coronary episode in their study, while we didn’t use this selection approach. 
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A lot of issues must be investigated before we can understand all mechanisms of interaction 
between thyroid and cardiovascular system, especially the natural course of CAD. It seems 
there is a great influence of individual differences of our patients with CAD and thyroid 
dysfunction on cardiovascular outcomes, and we should determine them in new large 
carefully designed controlled studies. 
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